CD34 and Miyoshi myopathy: Thus, further analysis is required to evaluate the efficacy of anti-TIGIT mAbs, with or without PD-1/PD-L1 blockade, on CD34+ and CD34− MM cells to clarify the significance of the enhanced PD-1 pathways in CD34+ MM cells.